Cargando…
Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
ABSTRACT—: We evaluated whether droxidopa, a prodrug converted to norepinephrine, is beneficial in the treatment of symptomatic neurogenic orthostatic hypotension, which results from failure to generate an appropriate norepinephrine response to postural challenge. Patients with symptomatic neurogeni...
Autores principales: | Biaggioni, Italo, Freeman, Roy, Mathias, Christopher J., Low, Phillip, Hewitt, L. Arthur, Kaufmann, Horacio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott, Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354798/ https://www.ncbi.nlm.nih.gov/pubmed/25350981 http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04035 |
Ejemplares similares
-
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017) -
Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial
por: Kaufmann, Horacio, et al.
Publicado: (2014) -
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017) -
Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019) -
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
por: François, Clément, et al.
Publicado: (2016)